Overview

Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis

Status:
Completed
Trial end date:
1999-04-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Assess the safety and effectiveness of budesonide in patients with primary sclerosing cholangitis or primary biliary cirrhosis experiencing a suboptimal response to ursodeoxycholic acid. II. Estimate the efficacy of this therapy in these patient groups as a means of evaluating the feasibility of a long-term randomized trial.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator:
Mayo Clinic
Treatments:
Budesonide